Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination.

Phase 4

Completed

Conditions: Acellular Pertussis
Tetanus
Diphtheria

Interventions: Biological: Boostrix TM

Registration Number: NCT00610168

Lead Sponsor: GlaxoSmithKline

Brief Summary: The purpose of this study is to assess the efficacy and safety of repeating dTpa booster in adults 10 years after previous booster vaccination with dTpa in a prior clinical study. Only subjects who received booster vaccination in the previous clinical study are eligible for participation in this study.

Detailed Description: This Protocol Posting has been updated in order to comply with FDA AA, Sep 2007.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 82

Inclusion Criteria

Subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study.
Subjects who have received dTpa vaccine or Td and pa vaccines in study 263855/004.
A male or female subject, recruited 10 years after booster vaccination in study 263855/004.
Healthy subjects as established by medical history and clinical examination before entering into the study.
If the subject is female, she must be of non-childbearing potential, or, if of childbearing potential, she must use adequate contraception for 30 days prior to vaccination and continue for 2 months after completion of the vaccination series.
Written informed consent obtained from the subject.

Exclusion Criteria

Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the booster dose of study vaccine, or planned use during the study period.
Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the booster dose.
Administration of a vaccine not foreseen by the study protocol within 30 days prior to booster vaccination or planned administration during the active study period.
Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.
Previous booster vaccination against tetanus, diphtheria or pertussis since the last dose received in study 263855/004.
History of documented diphtheria, tetanus, or pertussis diseases.
Any confirmed or suspected immunosuppressive or immunodeficiency condition, based on medical history and physical examination.
History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
Administration of immunoglobulins and/or any blood products within the three months preceding the booster dose or planned administration during the study period.
Occurrence of transient thrombocytopenia or neurological complications following an earlier immunisation against diphtheria and/or tetanus.
Occurrence of any of the following adverse event after a previous administration of a DTP vaccine :
- hypersensitivity reaction to any component of the vaccine,
- encephalopathy of unknown aetiology occurring within 7 days following previous vaccination with pertussis-containing vaccine,
- fever >= 40°C within 48 hours of vaccination not due to another identifiable cause,
- collapse or shock-like state (hypotonic-hyporesponsiveness episode) within 48 hours of vaccination,
- convulsions with or without fever, occurring within 3 days of vaccination.
Acute disease at the time of enrolment.
Pregnant or lactating female.
Female planning to become pregnant or planning to discontinue contraceptive precautions within 2 months after completion of the vaccination series.

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
BOOSTRIX II GROUP	Boostrix TM	Subjects, who had received Wyeth's (formerly Lederle) combined adult diphtheria and tetanus vaccine and GSK Biologicals' acellular pertussis vaccine in the primary study (263855/004), received one booster dose of Boostrix™ vaccine in this study, administered as an intramuscular injection into the deltoid region of the non-dominant arm.
BOOSTRIX I GROUP	Boostrix TM	Subjects, who had received Boostrix™ vaccine in the primary study (263855/004), received one additional booster dose of Boostrix™ vaccine in this study, administered as an intramuscular injection into the deltoid region of the non-dominant arm.

Primary Outcome Measures

Name	Time	Method
Number of Subjects With Anti-diphtheria (Anti-DT) and Anti-tetanus Toxoids (Anti-TT) Antibody Concentrations Above the Cut-offs	At Month 1	The antibody concentrations cut-offs assessed were: equal to or above (≥) 0.1 international units per milliliter (IU/mL) and ≥ 1 IU/mL.

Secondary Outcome Measures

Name	Time	Method
Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Haemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN) Antibody Concentrations	At Month 0 (PRE) and Month 1 (POST)	Concentrations are presented as geometric mean concentrations (GMCs), expressed in ELISA units per millilitre (EL.U/mL).
Number of Subjects With Serious Adverse Events (SAEs)	For safety assessment Boostrix I Group and Boostrix II Group were pooled (Pooled Group)	Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
Number of Seropositive Subjects for Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Haemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN)	At Month 0 (PRE) and Month 1 (POST)	A seropositive subject was defined as a subject with anti-PT, anti-FHA and anti-PRN antibody concentrations ≥ 5 ELISA unit per milli-liter (EL.U/ml)
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	During the 4-day (Day 0-3) follow-up period after booster vaccination	Assessed solicited general symptoms were fatigue, fever \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\], headache and gastrointestinal symptoms. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.
Number of Subjects With Unsolicited Adverse Events (AEs)	During the 31-day (Day 0-30) follow-up period after booster vaccination	An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.
Number of Subjects With Booster Response to Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Haemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN)	At Month 1	Booster response was defined as appearance of antibodies in subjects who were seronegative at the pre-vaccination time point (i.e. with concentrations \< 5 El.U/mL) or at least 2-fold increase of prevaccination antibody concentrations in subjects who were seropositive at the pre-vaccination time point (i.e. with concentrations ≥5 El.U/mL.
Number of Subjects With Any and Grade 3 Solicited Local Symptoms	During the 4-day (Day 0-3) follow-up period after booster vaccination	Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 50 millimeters (mm) of injection site.
Anti-diphtheria (Anti-DT) and Anti-tetanus Toxoids (Anti-TT) Antibody Concentrations	At Month 0 (PRE) and Month 1 (POST)	Concentrations are presented as international units per millilitre (IU/mL).